Table 1.
Comparison of baseline data between the model and validation groups
| Variable | Total | Training Group (n=391) | Validation Group (n=193) | Statistic | P-value |
|---|---|---|---|---|---|
| Myelosuppression | |||||
| Yes | 412 (70.55%) | 280 (71.61%) | 132 (68.39%) | 0.644 | 0.422 |
| No | 172 (29.45%) | 111 (28.39%) | 61 (31.61%) | ||
| Gender | |||||
| Male | 461 (78.94%) | 308 (78.77%) | 153 (79.27%) | 0.020 | 0.889 |
| Female | 123 (21.06%) | 83 (21.23%) | 40 (20.73%) | ||
| Treatment Regimen | |||||
| Docetaxel + Platinum | 173 (29.62%) | 119 (30.43%) | 54 (27.98%) | 1.143 | 0.767 |
| Gemcitabine + Platinum | 114 (19.52%) | 75 (19.18%) | 39 (20.21%) | ||
| Pemetrexed + Platinum | 156 (26.71%) | 107 (27.37%) | 49 (25.39%) | ||
| Others | 141 (24.14%) | 90 (23.02%) | 51 (26.42%) | ||
| Targeted Therapy | |||||
| Yes | 69 (11.82%) | 48 (12.28%) | 21 (10.88%) | 0.241 | 0.623 |
| No | 515 (88.18%) | 343 (87.72%) | 172 (89.12%) | ||
| First Chemotherapy | |||||
| Yes | 318 (54.45%) | 210 (53.71%) | 108 (55.96%) | 0.264 | 0.608 |
| No | 266 (45.55%) | 181 (46.29%) | 85 (44.04%) | ||
| Age (years) | 62.90±7.77 | 62.95±7.73 | 62.80±7.87 | 0.224 | 0.823 |
| BMI (kg/m2) | 22.20±3.18 | 22.24±3.00 | 22.11±3.53 | 0.460 | 0.646 |
| White Blood Cell Count (109/L) | 6.45±2.53 | 6.41±2.49 | 6.51±2.63 | 0.451 | 0.652 |
| Neutrophil Count (109/L) | 4.19 [2.76, 5.54] | 4.14 [2.88, 5.36] | 4.21 [2.61, 5.97] | 0.414 | 0.679 |
| Hemoglobin (g/L) | 124.34±17.74 | 124.09±17.64 | 124.84±17.96 | 0.479 | 0.632 |
| Platelet Count (109/L) | 227.61±81.88 | 228.27±82.23 | 226.29±81.37 | 0.274 | 0.784 |
| Total Protein (g/L) | 67.10±6.16 | 67.10±6.32 | 67.11±5.84 | 0.021 | 0.983 |
Note: BMI = Body Mass Index; “Others” in Treatment Regimen includes etoposide + platinum and paclitaxel + platinum.